Immunotherapy for Unresectable Pancreas Cancer: A Phase 1 Study of Intratumoral Recombinant Fowlpox PANVAC (PANVAC-F) Plus Subcutaneous Recombinant Vaccinia PANVAC (PANVAC-V), PANVAC-F and Recombinant Granulocyte-Macrophage Colony Stimulating Factor (rH-GM-CSF)
Latest Information Update: 27 Oct 2025
At a glance
- Drugs CV 301 (Primary) ; Falimarev; Falimarev; Inalimarev; Sargramostim
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
Most Recent Events
- 25 Apr 2025 Planned End Date changed from 23 Apr 2025 to 23 Apr 2026.
- 24 Apr 2024 Planned End Date changed from 14 Apr 2024 to 23 Apr 2025.
- 27 Apr 2023 Planned End Date changed from 14 Apr 2023 to 14 Apr 2024.